Key features and details
- Rabbit polyclonal to galectin 9/Gal-9
- Suitable for: IHC-P, WB, ELISA, ICC/IF
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Product nameAnti-galectin 9/Gal-9 antibody
See all galectin 9/Gal-9 primary antibodies
DescriptionRabbit polyclonal to galectin 9/Gal-9
This antibody detects endogenous levels of total galectin 9/Gal-9 protein.
Tested applicationsSuitable for: IHC-P, WB, ELISA, ICC/IFmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to Human galectin 9/Gal-9 aa 51-100 (internal sequence).
Database link: O00182
- NIH/3T3 cells. Extracts from HepG2 cells, human lymphoma
Previously labelled as galectin 9.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
without Mg2+ and Ca2+
Concentration information loading...
PurityProtein A purified
Purification notesThe antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Our Abpromise guarantee covers the use of ab69630 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 4 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|WB||1/500 - 1/1000. Detects a band of approximately 40 kDa (predicted molecular weight: 40 kDa).|
|ICC/IF||1/500 - 1/1000.|
FunctionBinds galactosides. Has high affinity for the Forssman pentasaccharide. May play a role in thymocyte-epithelial interactions relevant to the biology of the thymus. Inhibits cell proliferation. It is a ligand for HAVCR2/TIM3. Induces T-helper type 1 lymphocyte (Th1) death. Isoform Short acts as an eosinophil chemoattractant.
Tissue specificityPeripheral blood leukocytes and lymphatic tissues. Overexpressed in Hodgkin disease tissue.
Sequence similaritiesContains 2 galectin domains.
DomainContains two homologous but distinct carbohydrate-binding domains.
Cellular localizationCytoplasm. Secreted. May also be secreted by a non-classical secretory pathway.
- Information by UniProt
- 36 kDa beta-galactoside-binding lectin antibody
- Ecalectin antibody
- Gal-9 antibody
Immunofluorescence analysis of NIH/3T3 cells using ab69630 at 1/500 dilution, with (right panel) or without (left panel) the immunising peptide.
All lanes : Anti-galectin 9/Gal-9 antibody (ab69630) at 1/500 dilution
Lane 1 : Extracts from HepG2 cells
Lane 2 : Extracts from HepG2 cells with immunising peptide at 5 µg
Lysates/proteins at 5 µg per lane.
Predicted band size: 40 kDa
Observed band size: 40 kDa
Ab69630 recognizes the partial tagged recombinant Human galectin 9/Gal-9 protein (galectin 1 domain only) which has an expected molecular weight of 19 kDa.
ab69360 (4µg/ml) staining galectin 9 / Gal-9 in human lymphoma using an automated system (DAKO Autostainer Plus). Using this protocol there is cytoplasmic and secreted staining throughout the tumour.
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer EDTA pH 9.0 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.
ab69630 has been referenced in 10 publications.
- Huang N et al. Spleen-Associated Effects on Immunity in Hepatitis B Virus-Related Cirrhosis with Portal Hypertension. J Interferon Cytokine Res 39:95-105 (2019). PubMed: 30676849
- Jia J et al. Galectins Control mTOR in Response to Endomembrane Damage. Mol Cell 70:120-135.e8 (2018). PubMed: 29625033
- Choi SI et al. Prognostic value of tumoral expression of galectin-9 in gastric cancer. Turk J Gastroenterol 28:166-170 (2017). PubMed: 28492371
- Stromnes IM et al. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res 5:978-991 (2017). PubMed: 29066497
- Labrie M et al. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Sci Rep 7:13244 (2017). PubMed: 29038585
- Hou N et al. T-cell immunoglobulin and mucin domain-containing protein-3 and galectin-9 protein expression: Potential prognostic significance in esophageal squamous cell carcinoma for Chinese patients. Oncol Lett 14:8007-8013 (2017). PubMed: 29344243
- Severson JJ et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res 3:620-30 (2015). Human . PubMed: 25701326
- Cho SJ et al. Peroxisome proliferator-activated receptor ? upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer. Int J Cancer 136:810-20 (2015). PubMed: 24976296
- Jiang J et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One 8:e81799 (2013). IHC-P ; Human . PubMed: 24339967
- Alam S et al. Galectin-9 expression in endothelial cells is positively regulated by histone deacetylase 3. J Biol Chem : (2011). WB, ICC/IF ; Human . PubMed: 22027828